Displaying drugs 14926 - 14950 of 15559 in total
Alpha-1-acid glycoprotein
Investigational
ECT204
ECT204 is an autologous T-cell therapy whereby T cells are genetically modified to target tumor-specific antigens.
Investigational
Allogeneic natural killer cells
Investigational
MaaT013
MaaT013 is an allogeneic fecal microbiota therapy. It is being investigated for the treatment of Graft-Versus-Host Disease.
Investigational
Allogeneic human pancreatic islets of Langerhans
Investigational
Autologous CD4+CD25hiFoxP3+regulatory T cells
Investigational
Avoplacel
Avoplacel (PLX-R18) is an allogeneic cell therapy under investigation for the treatment of acute radiation syndrome.
Investigational
Rugonersen
Rugonersen is a locked nucleic acid antisense oligonucleotide under investigation for the treatment of Angelman Syndrome.
Investigational
Ulefnersen
Investigational
RC88
RC88 is an antibody-drug conjugate comprising a humanized anti-mesothelin monoclonal antibody conjugated to monomethyl auristatin E (MMAE).
Investigational
HLX-58
HLX-58 is an investigational monoclonal antibody targeted against claudin 18.2.
Investigational
rAAV1-CB-hAAT
rAAV1-CB-hAAT is a recombinant adeno-associated virus alpha 1-antitrypsin vector.
Investigational
BVX-001
BVX001 is a a novel, first-in-class CD33/CD7-directed antibody-drug conjugate.
Investigational
Lusvertikimab
Investigational
GXC-301
Investigational
Ubamatamab
Ubamatamab is under investigation in clinical trial NCT03564340 (Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers).
Investigational
Visugromab
Visugromab is under investigation in clinical trial NCT06059547 (Neoadjuvant Immunotherapy in Combination With the Anti-gdf-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer).
Investigational
Plamotamab
Plamotamab is under investigation in clinical trial NCT05328102 (Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)).
Investigational
Rilvegostomig
Rilvegostomig is under investigation in clinical trial NCT06109779 (Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (Artemide-biliary01)).
Investigational
Remternetug
Remternetug is under investigation in clinical trial NCT05463731 (A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)).
Investigational
Plozasiran
Plozasiran is under investigation in clinical trial NCT05089084 (Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)).
Investigational
Lunsekimig
Lunsekimig is under investigation in clinical trial NCT06102005 (Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma).
Investigational
Displaying drugs 14926 - 14950 of 15559 in total